Introduction
Vancomycin exhibits time-dependent bactericidal activity against most Gram-positive bacteria [1] . However, experimental models in neutropenic mice have shown some concentration-dependent activity [maximum drug concentration/minimum inhibitory concentration ratio (C max /MIC)], with advantages also evident when the area under the concentration-time curve (AUC) to MIC ratio (AUC/MIC) is maximised [2] . Therefore, the question remains whether intermittent dosing or continuous infusion is preferred.
Compared with intermittent infusion, continuous infusion of vancomycin is cheaper
and logistically more convenient, achieves target concentrations faster, results in less variability in serum concentrations and requires less therapeutic drug monitoring (TDM) [3] . Furthermore, in patients with normal renal function, vancomycin in continuous infusion is associated with a slower onset of nephrotoxicity [4] .
The Intensive Care Unit at GZA St Vincentius Hospital (Antwerp, Belgium) has been administering the standard vancomycin dosage (2000 mg intravenous daily, adjusted to the patient's renal function if necessary) by continuous infusion. The aim of this study was, as previously described by Pea et al. [5] , to assess retrospectively the 
Discussion
Vancomycin exhibits time-dependent antibacterial activity and no in vitro concentration-dependent killing effect against staphylococci [7] . Given these pharmacodynamic characteristics, one would predict that the time that the vancomycin serum level exceeds the MIC would be the pharmacodynamic parameter that most strongly correlates with efficacy [5] .
In the era of increasing resistance among micro-organisms, optimal dosage of vancomycin has become extremely important. Development of staphylococcal resistance to vancomycin has been associated with prolonged exposure to low M a n u s c r i p t 6 serum concentrations of the drug [8] . Furthermore, a significantly higher mortality rate is associated with meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia due to strains with vancomycin MICs >1 mg/L [9] . Therefore, large intermittent daily doses with the intent of achieving a trough concentration (C min ) of 15-20 mg/L in all patients may be used, but the unacceptably increased risk of nephrotoxicity recently documented in patients with very high C min during intermittent administration of highdose vancomycin argues against this choice [10] . Accordingly, application of continuous infusion with a target plateau concentration of 20-25 mg/L may be helpful in maximising the pharmacodynamics of vancomycin against staphylococcal infections while avoiding the risk of nephrotoxicity. Continuous infusion of vancomycin to obtain plateau concentrations of 20-25 mg/L is safe and shows good clinical efficacy [3] . The efficacy of vancomycin is optimal when the 24-h AUC/MIC ratio is ≥400 [11] . To achieve this target for S. aureus strains with MICs of 1 mg/L, a continuous serum concentration of 20 mg/L is needed [11] . However, as a tendency towards increasing vancomycin MICs (≥1 mg/L) in S. aureus clinical isolates is already being reported, a plateau concentration of vancomycin of 25 mg/L seems more appropriate [12] . Moreover, the pharmacokinetics of vancomycin can be significantly altered in critically ill patients. As an increased volume of distribution and/or increased drug clearance can result in lower vancomycin concentrations, administration of vancomycin by continuous infusion may enable more consistent attainment of target concentrations [7] . The present results show that, in critically ill patients with normal renal function, a daily dose of 3000 mg of vancomycin in continuous infusion (following a loading dose) is required to achieve a plateau concentration of 25 mg/L. Only recently, Revilla et al. [13] found, based on a M a n u s c r i p t 7 population model using Monte Carlo simulations, that a dose of 3 g vancomycin was needed for an adequate response in patients with S. aureus infections.
Using the target of 25 mg/L, the risk of nephrotoxicity is rather limited. In a multivariate analysis, Ingram et al. [14] found that nephrotoxicity was associated with vancomycin concentrations of 28 mg/L. The same authors recently reported that in adult outpatients with normal renal function, vancomycin by continuous infusion was associated with a slower onset of nephrotoxicity [4] . Furthermore, Hutschala et al.
[15] showed a tendency for less nephrotoxicity with continuous infusion compared with intermittent infusion of vancomycin.
In conclusion, these results show that in critically ill patients, following a loading dose of 1000 mg, a daily dose of 3000 mg of vancomycin in continuous infusion is needed to achieve target serum concentrations of 25 mg/L. In patients with decreased renal function, a nomogram based on the Cockcroft-Gault formula can be used for dose adjustment.
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